ACC Sandoz

Acetylcysteine Sandoz 200 mg: One effervescent tablet contains 200 mg acetylcysteine.
Acetylcysteine Sandoz 600 mg: One effervescent tablet contains 600 mg acetylcysteine.
Excipients/Inactive Ingredients: Anhydrous citric acid, Sodium hydrogen carbonate, Anhydrous sodium carbonate, Mannitol, Anhydrous lactose, Ascorbic acid, Sodium cyclamate (for 600 mg only), Sodium citrate, Saccharin sodium, Blackberry flavour "B" (contains vanillin, maltodextrin, mannitol (E 421), gluconolactone (E 575), sorbitol (E 420), magnesium hydroxide carbonate (E 504 II), colloidal anhydrous silica (E 551)).

Pharmacotherapeutic group: Cough and cold preparations; Mucolytics. ATC Code: R05CB01.
Pharmacology: Pharmacodynamics: Acetylcysteine is a derivative of the amino acid cysteine. The efficacy of acetylcysteine is secretolytic and secretomotoric in the area of the respiratory tract. It is discussed that it splits off the interconnecting disulphide bonds between the mycopolysaccharide chains and that it has a depolymerizing effect on DNA-chains (in purulent mucus). Due to these mechanisms, the viscosity of mucus should be reduced.
An alternative mechanism of acetylcysteine is meant to be based on the capacity of its reactive SH group to bind chemical radicals and to detoxify them in this way.
Furthermore, acetylcysteine contributes to an increase in glutathione synthesis, which is important for the detoxification of noxae. This provides the explanation for its antidotal effect in paracetamol intoxication.
A protective effect on the frequency and severity of bacterial exacerbations - when acetylcysteine is administered prophylactically - is described in patients with chronic bronchitis/mucoviscidosis.
Pharmacokinetics: Absorption: Following oral administration, acetylcysteine is rapidly and almost completely absorbed and metabolized in the liver to cysteine, the pharmacologically active metabolite, as well as to diacetylcystine, cystine and further mixed disulphides.
Distribution: Due to the high first-pass effect, the bioavailability of orally administered acetylcysteine is very low (approx. 10%). In humans, maximum plasma concentrations are achieved after 1-3 hours with the maximum plasma concentration of the metabolite cysteine in the range of approx. 2 μmol/l. The protein binding of acetylcysteine was determined to be about 50%.
Biotransformation: Acetylcysteine and its metabolites occur in three different forms in the organism: partially in free form, partially bound to proteins via labile disulphide bonds and partially as incorporated amino acid. Acetylcysteine is excreted almost exclusively in the form of inactive metabolites (inorganic sulphates, diacetylcystine) via the kidneys. The plasma half-life of acetylcysteine is approximately 1 hour and is mainly determined by the rapid hepatic biotransformation. Impaired hepatic function therefore leads to prolonged plasma half-lives of up to 8 hours.
Elimination: Pharmacokinetic studies with intravenous administration of acetylcysteine revealed a distribution volume of 0.47 l/kg (in total) or 0.59 l/kg (reduced); the plasma clearance was determined to be 0.11 l/h/kg (in total) and 0.84 l/h/kg (reduced), respectively. The elimination half-life after intravenous administration is 30-40 minutes while excretion follows three-phase kinetics (alpha, beta, and terminal gamma phase).
Acetylcysteine crosses the placenta and is detected in cord blood. No information is available regarding excretion into breast milk.
No knowledge is available concerning the behaviour of acetylcysteine at the blood-brain barrier in humans.
Toxicology: Preclinical safety data: Acute toxicity: The acute toxicity in animal experiments is low. For the treatment of overdoses, see Overdosage.
Chronic toxicity: Studies in various animal species (rat, dog) with a duration of up to one year did not show any pathological alterations.
Tumorigenic and mutagenic potential: No mutagenic effects of acetylcysteine are to be expected. An in vitro test was negative.
No studies of a tumorigenic potential of acetylcysteine have been carried out.
Reproductive toxicology: No malformations were detected in embryotoxicity studies in rabbits and rats. Studies of fertility and perinatal or postnatal toxicity were negative.
Acetylcysteine passes the placenta in rats and was detected in amniotic fluid. The concentration of the metabolite L-cysteine is above the maternal plasma concentration in placenta and foetus for up to 8 hours after oral administration.

Used to dissolve mucus in the respiratory tract. Relieve cough with mucus.

Posology: 200 mg: If not otherwise prescribed, the following dosage is recommended for Acetylcysteine Sandoz: Adults and adolescents from 14 years of age: 1 effervescent tablet 2-3 times daily (equivalent to 400-600 mg acetylcysteine per day).
Children and adolescents 6-14 years of age: 1 effervescent tablet twice daily (equivalent to 400 mg acetylcysteine per day).
Children 2-5 years of age: ½ effervescent tablet 2-3 times daily (equivalent to 200-300 mg acetylcysteine per day).
600 mg: If not otherwise prescribed, the following dosage is recommended for Acetylcysteine Sandoz: Adults and adolescents from 14 years of age: ½ effervescent tablet twice daily or 1 effervescent tablet once daily (equivalent to 600 mg acetylcysteine per day).
Method of administration: The effervescent tablets are taken dissolved in a glass of water after meals.
Duration of use: 200 mg: Acetylcysteine Sandoz should not be taken for more than 4-5 days without medical advice.
600 mg: Acetylcysteine Sandoz should not be taken for more than 4-5 days without medical advice.

No case of toxic overdose has been observed to date in association with oral pharmaceutical forms of acetylcysteine. Volunteers were treated with a dose of 11.6 g acetylcysteine/day over 3 months without observing any severe undesirable effects. Oral doses up to 500 mg acetylcysteine/kg BW were tolerated without any symptoms of intoxication.
Symptoms of intoxication: Overdoses may lead to gastrointestinal symptoms such as nausea, vomiting and diarrhoea. Infants are at risk of hypersecretion.
Therapeutic measures in case of an overdose: If necessary, according to the symptoms.
Experience gained from intravenous acetylcysteine treatment of paracetamol intoxication is available in humans with maximum daily doses of up to 30 g acetylcysteine. Intravenous administration of extremely high acetylcysteine concentrations led to partially irreversible "anaphylactoid" reactions, particularly in connection with rapid administration.

Hypersensitivity to acetylcysteine or to any of the excipients listed in Description.
200 mg: On account of the high content of active substance, Acetylcysteine Sandoz must not be used in children of less than 2 years of age and whole tablets of Acetylcysteine Sandoz must not be used in children of less than 6 years of age.
600 mg: On account of the high content of active substance, Acetylcysteine Sandoz must not be used in children of less than 14 years of age.

The occurrence of severe skin reactions such as Stevens-Johnson syndrome and Lyell's syndrome has very rarely been reported in temporal connection with the use of acetylcysteine. If cutaneous and mucosal changes newly occur, medical advice should be sought without delay and use of acetylcysteine be terminated (see also Adverse Reactions).
Cave during use in patients with bronchial asthma and in patients with anamnestic ulcers.
Caution is advised in patients with histamine intolerance. Longer-term therapy should be avoided in these patients, as Acetylcysteine has an effect on histamine metabolism and may lead to symptoms of intolerance (e.g. headache, vasomotor rhinitis, itching).
The use of acetylcysteine, especially in early treatment can lead to liquefaction and thus to an increase in volume of bronchial secretions. If the patient is unable to cough up enough of this, appropriate measures (such as postural drainage and aspiration) should be performed.
Acetylcysteine Sandoz contains sorbitol, lactose and sodium.
200 mg: This medicinal product contains up to 20 mg sorbitol in each effervescent tablet. Patients with hereditary fructose intolerance (HFI) should not take this medicinal product.
This medicinal product contains 70 mg lactose per effervescent tablet. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
This medicinal product contains 4.3 mmol (99 mg) sodium per effervescent tablet, equivalent to 5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
600 mg: This medicinal product contains up to 40 mg sorbitol in each effervescent tablet.
This medicinal product contains 70 mg lactose per effervescent tablet. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
This medicinal product contains 6.0 mmol (139 mg) sodium per effervescent tablet, equivalent to 7% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Effects on ability to drive and use machines: Acetylcysteine has no influence on the ability to drive and use machines.

Fertility: Data concerning effects of acetylcysteine on human fertility are not available. In animal studies, no harmful effects on fertility were observed for therapy-relevant doses of acetylcysteine (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Pregnancy: There are no adequate clinical data from the use of acetylcysteine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Whenever possible, use during pregnancy should be avoided and only take place after a strict benefit-risk assessment.
Breast-feeding: No information is available regarding excretion of acetylcysteine or its metabolites into breast milk. A risk for the breast-fed child cannot be excluded. Use during lactation should only take place after a strict benefit-risk assessment.

The evaluation of undesirable effects is based on the following information on frequencies: Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known (cannot be estimated from the available data). (See table.)

Click on icon to see table/diagram/image

In very rare cases, severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in temporal association with the use of acetylcysteine. In most of these reported cases, at least one additional drug that could potentially have intensified the described mucocutaneous effects was being taken at the same time.
If skin or mucous membrane abnormalities develop, medical advice should therefore immediately be sought and the use of acetylcysteine discontinued.
In addition, the occurrence of haemorrhages in association with the administration of acetylcysteine has very rarely been reported, partially with hypersensitivity reactions. A decreased blood platelet aggregation in the presence of acetylcysteine has been confirmed by various studies. The clinical relevance has not yet been clarified to date.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed.

Interaction studies have only been performed in adults.
Combined use of Acetylcysteine with antitussives (cough-relieving agents) may cause a dangerous secretory congestion due to the reduced cough reflex, so that an especially careful diagnosis is required for this combination treatment.
Antibiotics: Reports to date on an inactivation of antibiotics (tetracyclines, aminoglycosides, penicillins) due to acetylcysteine exclusively refer to in vitro experiments in which the relevant substances were mixed directly. Nevertheless for safety reasons, oral antibiotics should be administered separately and at an interval of at least 2 hours. This does not apply to cefixime and loracarbef.
Activated carbon in high doses: The use of activated charcoal may reduce the effect of acetylcysteine.
Acetylcysteine/glyceryl trinitrate: Co-administration of acetylcysteine can result in an enhancement of vasodilator and antiplatelet effects of glyceryl trinitrate (nitroglycerine).
If a common treatment with nitroglycerin and acetylcysteine is considered necessary, the patient should be monitored for a potential hypotension, which could be serious and may be indicated by headache.
Changes in the determination of laboratory parameters: Acetylcysteine may affect the colorimetric assay of salicylates; in urine tests, acetylcysteine may influence the results of the determination of ketone bodies.
The dissolution of acetylcysteine formulations together with other medicinal products is not recommended.

Incompatibilities: Not applicable.
Special precautions for disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Shelf life: Sachets: 3 years.
Special precautions for storage: Sachets: Do not store above 30°C.

Cough & Cold Preparations

R05CB01 - acetylcysteine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.

NDD